AMSBIO is a knowledgeable supplier of products dedicated to exosome research that includes high quality reagents and kits that are quick, affordable and easy to use.The latest addition to this portfolio is a new range of tools for isolating and purifying overall or specific exosome sub-populations from small volumes of sample in an efficient, faster and cheaper way. For applications that require total exosome isolation from biological fluids including plasma, serum and urine as well as cell culture media, AMSBIO has launched ExoPure™ Reagent - a fast and convenient one-step method…
Click here to view the August edition of Dates for Your Diary.
Hamburg-based Exit Games GmbH has entered into a strategic partnership with Skillz Inc.. As part of the strategic partnership, Skillz has acquired a minority interest in Exit Games in the amount of 50 million US dollars. A team of the international law firm Taylor Wessing, led by Hamburg-based partner Jens Wolf, advised Exit Games on all legal issues in connection with the transaction.
Exit Games is the developer of the well-known network and multiplayer engine Photon, which allows software developers to create and host synchronous real-time applications.
Exit Games has been a client of…
The international law firm Taylor Wessing, led by Frankfurt based M&A partner Stephan Doom and Phil Shepherd from London, provided comprehensive legal advice to the International Chemical Investors Group (ICIG) on the acquisition of the sulphuric acid production plant in Bilbao from INEOS Enterprises.
INEOS Sulphur Chemicals Spain SLU is Spain's largest dedicated manufacturer of sulphuric acid and oleum with applications ranging from the agricultural sector to chemical intermediates. The plant located in the harbour of Bilbao becomes part of the WeylChem Group, the fine chemicals…
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced that the United States Patent and Trademark Office (USPTO) has granted the Company a patent (U.S. Patent No. 11,033,569) protecting the composition of matter of F-star’s SB 11285, a second generation STING agonist. The patent protection is expected to continue to July 2037, not…
Cambridge’s Mission Therapeutics is to receive a milestone payment of $20 million from Wall Street-quoted AbbVie as part of a neurodegenerative disease collaboration.
Mission is a drug discovery and development company focused on targeting the ubiquitin pathway; the partners are progressing selected deubiquitylating enzyme (DUB) targets into the next phase of research.
In the second major milestone of the companies’ research and preclinical development alliance, AbbVie has nominated two DUB targets to progress to the next stage of drug discovery. This selection follows supportive data…
Cambridge, UK, 05 Aug 2021: o2h Ventures is delighted to announce an investment into BiVictriX Therapeutics, an emerging biotechnology company applying a novel approach to develop next-generation cancer therapies using insights derived from frontline clinical experience.
BiVictriX is dedicated to applying a novel approach in developing safer and effective cancer therapies, by revolutionizing cancer therapy and making curative treatments available to all; By delivering a broad pipeline of proprietary, first-in-class Bi-Cygni® therapeutics to enable potentially higher dosing and more…
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announced that it has entered into a clinical trial collaboration and supply agreement with MSD (Merck & Co., Inc., Kenilworth, NJ, USA), to evaluate the combination of FS120, F-star’s first-in-class dual-agonist tetravalent bispecific antibody targeting CD137 and OX40, with KEYTRUDA® (pembrolizumab), MSD’…
Cambridge, UK – 4 August 2021 – Healx, the AI-powered, patient-inspired technology company pioneering the next generation of drug discovery, today announced an exciting partnership with Ono Pharmaceutical Co., Ltd., one of Japan’s largest pharmaceutical companies and a global leader in the field of R&D-orientated drug discovery. The collaboration will leverage Healx’s innovative indication expansion technology to identify new disease indications with high unmet needs that could be treated by Ono’s proprietary assets.
Healx are experts in the field of AI-powered drug discovery and…